Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Famitinib malate + camrelizumab neoadjuvant phase II study in locally advanced cervical cancer
ChiCTR2600136030Phase 2Not yet recruiting
- Sponsor
- Fujian Medical University Cancer Hospital
- Start
- Nov 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of famitinib and camrelizumab in Cervical Cancer (CC), sponsored by Fujian Medical University Cancer Hospital. Primary endpoint: Pathological complete response rate. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
famitinibcamrelizumab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on ChiCTR2600136030.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600136030.